Who founded Draig Therapeutics?

Draig Therapeutics was founded by John Atack, Simon Ward.

Who are Draig Therapeutics's investors?

Draig Therapeutics's investors include Access Biotechnology, Canaan Partners, Sanofi Ventures, SV Health Investors, SR One Capital Management, British Business Bank, Janus Henderson Investors.

How much funding has Draig Therapeutics raised?

Draig Therapeutics has disclosed $65M raised across 1 round.

Where is Draig Therapeutics headquartered?

Draig Therapeutics is headquartered in Cardiff, GB.

Draig Therapeutics

Cardiff, GB · 44 employees on LinkedIn · 9 known investors

Find your way into Draig Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

393 people can intro you to Simon

Ask Laetitia Schwab to introduce you to Simon Ward

You →Laetitia · together at Draig Therapeutics →Simon

Your email: who you already know at Draig Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Draig Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders. The company was founded by Cardiff University and SV Health Investors in 2024.

Biotech Deep Tech Digital Health Medical Devices

Founders & leadership

John AtackHead of Biology & Founder

Simon Ward Chief Scientific Officer & FounderSimon Ward is a neuroscience researcher with over 25 years of experience in pharmaceutical, biotech, and academic settings. He holds a Sêr Cymru Professorship in Translational Drug Discovery at Cardiff University, where he founded the Medicines Discovery Institute, and is Founder and Chief Scientific Officer of Draig Therapeutics, a clinical-stage biotech company developing neuropsychiatric therapies.

Investors · 9

Access Biotechnology✓ confirmed by Draig TherapeuticsNew York

How we know: Access Biotechnology's portfolio page · the company's own site · Not right? Tell us

Canaan Partners✓ confirmed by Draig TherapeuticsStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Sanofi Ventures✓ confirmed by Draig TherapeuticsCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the company's own site · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

SV Health Investors✓ confirmed by Draig TherapeuticsLondon · $1M – $20Mvia Charles Dunn · led

How we know: SV Health Investors's portfolio page · the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

British Business BankreportedSheffield

How we know: pulse2.com · funding news · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: pulse2.com · funding news · Not right? Tell us

Also in the syndicate · 2

Deep Track CapitalleadJefferson Life Sciences

Funding

SEC filings, press & company announcements

$65M disclosed across 1 round · 2026

$65MSeries BJul 2026 · 2 sources
Deep Track Capital (lead), British Business Bank, Janus Henderson Investors, Jefferson Life Sciences, Marshall Wace
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Companies House · registry record

View on Companies House ↗

Registered name: DRAIG THERAPEUTICS LTD
Company number: 13405365
Status: Active
Company type: Private limited company
Incorporated: 18 May 2021
Registered office: Sbarc Spark, Maindy Road, Cardiff, CF24 4HQ
Nature of business (SIC): 72110 — Research and experimental development on biotechnology
Accounts: last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement: last made up to 17 May 2026 · next due 31 May 2027

Current officers · 9

Samantha Louise Budd Haeberlein — director, appointed 5 Sept 2024
Colleen Cuffaro — director, appointed 10 Jun 2025
Charles Montfort Dunn — director, appointed 5 Sept 2024
Ivana Magovcevic-Liebisch — director, appointed 10 Nov 2025
Ruth Mitchell Mckernan — director, appointed 5 Sept 2024
Jodie Pope Morrison — director, appointed 17 Mar 2026
Liam Ratcliffe — director, appointed 10 Jun 2025
Laetitia Schwab — director, appointed 10 Jun 2025
Douglas Edward Williams — director, appointed 10 Jul 2025

Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Draig Therapeutics Raises $65M in Series B Fundingfinsmes.com · Jul 2026

Frequently asked questions

What does Draig Therapeutics do?: Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders. The company was founded by Cardiff University and SV Health Investors in 2024.
Who founded Draig Therapeutics?: Draig Therapeutics was founded by John Atack, Simon Ward.
Who are Draig Therapeutics's investors?: Draig Therapeutics's investors include Access Biotechnology, Canaan Partners, Sanofi Ventures, SV Health Investors, SR One Capital Management, British Business Bank, Janus Henderson Investors.
How much funding has Draig Therapeutics raised?: Draig Therapeutics has disclosed $65M raised across 1 round.
Where is Draig Therapeutics headquartered?: Draig Therapeutics is headquartered in Cardiff, GB.